Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALGS Aligos Therapeutics	$5.39 -6.1%	$5.66	$3.76 ▼ $46.80	$32.95M	2.76	202,581 shs	162,480 shs
BCLI Brainstorm Cell Therapeutics	$1.15 +2.7%	$1.11	$0.72 ▼ $8.10	$8.89M	0.35	356,244 shs	1.16 million shs
FGEN FibroGen	$0.31 -2.7%	$0.31	$0.18 ▼ $1.53	$31.46M	0.86	2.05 million shs	1.33 million shs
LVTX LAVA Therapeutics	$1.31 -1.1%	$1.25	$0.85 ▼ $2.53	$34.85M	0.46	159,071 shs	405,213 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALGS Aligos Therapeutics	0.00%	-2.00%	-10.61%	-68.05%	-64.66%
BCLI Brainstorm Cell Therapeutics	0.00%	+6.46%	-0.88%	-28.14%	-85.51%
FGEN FibroGen	0.00%	-5.67%	-8.09%	-23.78%	-73.39%
LVTX LAVA Therapeutics	0.00%	+2.34%	+5.65%	+1.55%	-44.96%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALGS Aligos Therapeutics	4.3541 of 5 stars	3.5	4.0	4.8	2.6	1.7	0.6
BCLI Brainstorm Cell Therapeutics	4.2765 of 5 stars	3.5	5.0	4.7	2.7	0.0	0.6
FGEN FibroGen	4.0919 of 5 stars	3.3	2.0	4.7	1.9	3.3	0.6
LVTX LAVA Therapeutics	2.3616 of 5 stars	3.0	5.0	0.0	3.0	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALGS Aligos Therapeutics	3.00	Buy	$70.00	1,198.70% Upside
BCLI Brainstorm Cell Therapeutics	3.00	Buy	$30.00	2,509.15% Upside
FGEN FibroGen	2.50	Moderate Buy	$10.00	3,112.34% Upside
LVTX LAVA Therapeutics	2.00	Hold	$3.17	141.73% Upside

Current Analyst Ratings Breakdown

Latest BCLI, LVTX, ALGS, and FGEN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/15/2025	LVTX LAVA Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
5/13/2025	FGEN FibroGen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
4/1/2025	FGEN FibroGen	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
3/31/2025	ALGS Aligos Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$70.00 ➝ $70.00
3/31/2025	LVTX LAVA Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$1.50 ➝ $1.50
3/18/2025	FGEN FibroGen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
3/11/2025	ALGS Aligos Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$75.00 ➝ $70.00

(Data available from 6/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALGS Aligos Therapeutics	$3.27M	10.08	N/A	N/A	$30.65 per share	0.18
BCLI Brainstorm Cell Therapeutics	N/A	N/A	N/A	N/A	($1.20) per share	N/A
FGEN FibroGen	$7.00M	4.50	N/A	N/A	($1.87) per share	-0.17
LVTX LAVA Therapeutics	$4.99M	6.91	N/A	N/A	$1.95 per share	0.67

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALGS Aligos Therapeutics	-$87.68M	-$17.51	N/A	N/A	N/A	-1,283.19%	-114.34%	-64.58%	8/5/2025 (Estimated)
BCLI Brainstorm Cell Therapeutics	-$17.19M	-$3.36	N/A	N/A	N/A	N/A	N/A	-528.56%	8/13/2025 (Estimated)
FGEN FibroGen	-$284.23M	-$0.10	N/A	N/A	N/A	-67.66%	N/A	-36.17%	8/5/2025 (Estimated)
LVTX LAVA Therapeutics	-$41.97M	-$1.04	N/A	N/A	N/A	N/A	-62.22%	-29.37%	8/19/2025 (Estimated)

Latest BCLI, LVTX, ALGS, and FGEN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	BCLI Brainstorm Cell Therapeutics	-$0.38	-$0.45	-$0.07	-$0.45	N/A	N/A
5/14/2025	Q1 2025	LVTX LAVA Therapeutics	-$0.37	-$0.13	+$0.24	-$0.13	N/A	N/A
5/12/2025	Q1 2025	FGEN FibroGen	$0.03	-$0.16	-$0.19	$0.05	$2.00 million	$2.70 million
5/6/2025	Q1 2025	ALGS Aligos Therapeutics	-$2.80	-$2.11	+$0.69	-$2.11	$0.33 million	$0.31 million
3/28/2025	Q4 2024	LVTX LAVA Therapeutics	-$0.32	-$0.14	+$0.18	-$0.14	$2.40 million	$2.50 million
3/17/2025	Q4 2024	FGEN FibroGen	-$0.08	-$0.08	N/A	$0.18	$24.91 million	$3.14 million
3/10/2025	Q4 2024	ALGS Aligos Therapeutics	-$2.63	-$13.08	-$10.45	-$13.08	$0.43 million	$0.63 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALGS Aligos Therapeutics	N/A	N/A	N/A	N/A	N/A
BCLI Brainstorm Cell Therapeutics	N/A	N/A	N/A	N/A	N/A
FGEN FibroGen	N/A	N/A	N/A	N/A	N/A
LVTX LAVA Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALGS Aligos Therapeutics	N/A	3.81	3.81
BCLI Brainstorm Cell Therapeutics	N/A	0.05	0.05
FGEN FibroGen	N/A	1.28	1.16
LVTX LAVA Therapeutics	N/A	5.36	5.36

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALGS Aligos Therapeutics	60.43%
BCLI Brainstorm Cell Therapeutics	14.33%
FGEN FibroGen	72.71%
LVTX LAVA Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
ALGS Aligos Therapeutics	8.75%
BCLI Brainstorm Cell Therapeutics	11.15%
FGEN FibroGen	1.98%
LVTX LAVA Therapeutics	0.79%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALGS Aligos Therapeutics	90	6.11 million	3.27 million	No Data
BCLI Brainstorm Cell Therapeutics	40	7.94 million	5.32 million	Optionable
FGEN FibroGen	570	101.04 million	98.78 million	Optionable
LVTX LAVA Therapeutics	60	26.31 million	26.08 million	Optionable

BCLI, LVTX, ALGS, and FGEN Headlines

Recent News About These Companies

Here's Why We're Watching LAVA Therapeutics' (NASDAQ:LVTX) Cash Burn Situation

May 16, 2025 | finance.yahoo.com

LAVA Therapeutics N.V.: LAVA Reports First Quarter 2025 Financial Results, Provides Business Update

May 15, 2025 | finanznachrichten.de

LAVA Reports First Quarter 2025 Financial Results, Provides Business Update

May 14, 2025 | globenewswire.com

LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation | LVTX Stock News

April 16, 2025 | gurufocus.com

LAVA Therapeutics Strengthens Balance Sheet with $5.1 Million Repayment Waiver from Netherlands Enterprise Agency

April 16, 2025 | quiverquant.com

LAVA Therapeutics (LVTX) Secures $5.1 Million Debt Waiver from Netherlands Enterprise Agency | ...

April 16, 2025 | gurufocus.com

LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation

April 16, 2025 | globenewswire.com

Lava Therapeutics reports Q4 EPS (14c) vs. (24c) last year

March 29, 2025 | markets.businessinsider.com

LAVA Therapeutics GAAP EPS of -$0.14, revenue of $4.99M

March 28, 2025 | seekingalpha.com

LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

March 28, 2025 | globenewswire.com

Analyst Downgrades LAVA Therapeutics, Sees Pipeline Overhang

February 28, 2025 | benzinga.com

Cautious Stance on LAVA Therapeutics Amid Strategic Review and Workforce Reduction

February 27, 2025 | tipranks.com

Lava Therapeutics announces evaluation of strategic options

February 26, 2025 | markets.businessinsider.com

LAVA Therapeutics (NASDAQ:LVTX) Stock Quotes, Forecast and News Summary

February 26, 2025 | benzinga.com

Lava Therapeutics trims workforce by 30% to preserve cash

February 25, 2025 | bizjournals.com

Serina Therapeutics Appoints Karen J. Wilson to Board of Directors

January 14, 2025 | quiverquant.com

LAVA Therapeutics Doses First Patient in Phase 1 Study of Bispecific Gammabody® LAVA-1266 for CD123-Expressing Blood Cancers

January 10, 2025 | quiverquant.com

LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers

January 10, 2025 | globenewswire.com

LAVA Therapeutics to Transition to U.S. Domestic Issuer

January 2, 2025 | tipranks.com

Leerink Partners Downgrades LAVA Therapeutics N.V. (LVTX)

December 13, 2024 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCLI, LVTX, ALGS, and FGEN Company Descriptions

Aligos Therapeutics NASDAQ:ALGS

$5.39 -0.35 (-6.10%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$5.31 -0.08 (-1.48%)

As of 05/30/2025 07:57 PM Eastern

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Brainstorm Cell Therapeutics NASDAQ:BCLI

$1.15 +0.03 (+2.66%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$1.14 -0.01 (-0.85%)

As of 05/30/2025 07:58 PM Eastern

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.

FibroGen NASDAQ:FGEN

$0.31 -0.01 (-2.72%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$0.30 -0.01 (-3.63%)

As of 05/30/2025 07:59 PM Eastern

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

LAVA Therapeutics NASDAQ:LVTX

$1.31 -0.02 (-1.13%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$1.30 -0.01 (-0.76%)

As of 05/30/2025 04:01 PM Eastern

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time